Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lamictal Pregnancy Monitoring Will Continue Following “FDA Alert”

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA issues leaflet to physicians and healthcare professionals regarding potential oral clefts in children exposed to Lamictal during first trimester of pregnancy.

You may also be interested in...



GSK’s Lamictal Adds Indication As Add-On Therapy For Grand Mal Seizures

Next in the pipeline for GSK’s epilepsy franchise is an XR formulation for once-daily dosing.

Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says

The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel